Modality
Small Molecule
MOA
WRNi
Target
TROP-2
Pathway
NF-κB
MSBCC
Development Pipeline
Preclinical
~Sep 2014
→ ~Dec 2015
Phase 1
~Mar 2016
→ ~Jun 2017
Phase 2
~Sep 2017
→ ~Dec 2018
Phase 3
~Mar 2019
→ ~Jun 2020
NDA/BLA
Sep 2020
→ Sep 2025
NDA/BLACurrent
NCT06774147
1,711 pts·MS
2020-09→2025-09·Completed
1,711 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-09-236mo agoPh3 Readout· MS
Trial Timeline
Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q4
NDA/BLA
Complet…
Catalysts
Ph3 Readout
2025-09-23 · 6mo ago
MS
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06774147 | NDA/BLA | MS | Completed | 1711 | PASI75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| NVS-4076 | Novartis | Preclinical | TROP-2 | |
| NVS-8902 | Novartis | Preclinical | TROP-2 | |
| ABB-1817 | AbbVie | Phase 3 | SHP2 | |
| BMY-7975 | Bristol-Myers Squibb | Phase 1 | MALT1 | |
| Zanumavacamten | GSK | Phase 2/3 | TROP-2 | |
| GSK-4334 | GSK | Preclinical | CD47 | |
| AMG-2752 | Amgen | Preclinical | MDM2 | |
| REG-7737 | Regeneron | Preclinical | CD123 | |
| VRT-5853 | Vertex Pharma | Phase 3 | Aβ | |
| Pemitapinarof | BeiGene | Approved | KRASG12C |